English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

118 ARTICLE SUMMARY Serum CA-125 is commonly used as a marker for ovarian cancer (1,2), although it can be elevated in nongynecological malignancy and benign gynecological disease (2). In this prospective study, serum CA-125 was measured preand postliver transplantation in 57 cirrhotic patients (67% men) as well as two patients with polycystic liver disease and abdominal distention without ascites. Ascitic CA-125 levels were determined in five patients who had paracentesis. Mesothelial CA125 staining was performed in 16 hepatectomy specimens. The mean serum CA-125 level pretransplant was 352±549 U/L (normal less than 37 U/L) and 46±49 U/L post-transplant (P<0.001). The mean ascitic CA-125 was 951±322 U/L compared with the mean serum level of 619±290 U/L (P<0.003). The CA-125 mesothelial staining grade was 0.8±1.4 and 1.5±1.1 in patients with normal and elevated serum CA-125 (P=0.37). The two patients with polycystic liver disease without ascites also had elevated CA-125. On multivariate analysis, ascites was the only predictive variable for elevated serum CA125.

Tumour Markers and Cirrhosis: The Ca-125 Who Came in From the Cold